Arrowhead Pharmaceuticals

This study tested a new drug called ARO-C3 in healthy volunteers and people with kidney diseases caused by an overactive immune system (C3 Glomerulopathy and IgA Nephropathy). The main goal was to check the drug's safety and how it moves through the body. Participants received on…

This study tested an experimental drug called ARO-APOC3 in 229 adults with severely high triglycerides (a type of blood fat). Participants received two injections of the drug or a placebo. The main goal was to see if the drug safely lowers triglyceride levels after 24 weeks, with…

This study tested a new drug called fazirsiran in 16 people with alpha-1 antitrypsin deficiency, a genetic condition that can cause liver damage. The goal was to see if the drug is safe and can reduce harmful protein buildup in the liver. Participants received multiple doses of t…

This early-stage study tested a new medicine called ARO-ANG3 in 93 healthy adults and people with high cholesterol or high triglycerides. The main goal was to see if the drug is safe and how the body processes it. This is a first step toward a possible new treatment for lipid dis…

This study tested a new drug, ARO-HSD, in 50 healthy people and patients with NASH, a serious fatty liver disease. The main goal was to see if the drug is safe and how the body processes it. This is an early-stage trial, so it focuses on safety and dosing, not on curing the disea…

This early-stage study tested the safety and how the body processes ARO-AAT in 45 healthy adults. The drug aims to lower abnormal protein levels that cause lung and liver damage in people with Alpha-1 Antitrypsin Deficiency. By focusing on safety first, this trial lays groundwork…

This study looked at the long-term safety of a drug called ARO-APOC3 in 418 adults with dyslipidemia (abnormal levels of fats in the blood). Participants who completed a previous 12-month study received the drug every 3 to 6 months. The main goal was to track side effects, and re…

This early-stage trial tested a new drug called ARO-HIF2 in 26 people with advanced clear cell kidney cancer that had worsened after at least two prior treatments. The goal was to find a safe dose and see if the drug could help control the disease. Participants received injection…

This study tested a new drug called fazirsiran in 40 people with alpha-1 antitrypsin deficiency, a genetic condition that can cause liver damage. The main goal was to see if the drug safely lowers levels of a harmful protein (Z-AAT) in the blood. Participants received multiple do…

This early-stage study tested a new medicine called ARO-APOC3 in healthy people and those with extremely high triglycerides (blood fats), including a rare genetic condition called familial chylomicronemia syndrome. The main goal was to check safety and how the drug moves through …

This study tested a new drug called ARO-HBV in healthy volunteers and people with chronic hepatitis B. The main goal was to check if the drug is safe and how the body processes it. A total of 114 people took part, and researchers monitored side effects and drug levels in the bloo…

This early-stage study tested an inhaled drug called ARO-MMP7 in 105 people, including healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. The main goal was to check safety and how the drug moves …

This study tested an experimental drug called plozasiran in 353 adults with mixed dyslipidemia, a condition with high triglycerides and cholesterol. Participants received either the drug or a placebo for 48 weeks while staying on a heart-healthy diet. The goal was to see if ploza…

This study tested an experimental drug called ARO-ANG3 in 204 adults with mixed dyslipidemia, a condition with high levels of fats like triglycerides and cholesterol in the blood. Participants received injections of the drug or a placebo to see if it safely lowers these fats. The…

This early-stage study tested an inhaled drug called ARO-RAGE in 127 healthy volunteers and people with asthma. The goal was to check safety and how the drug affects lung function. Participants received either the drug or a placebo, and researchers monitored side effects and brea…

This early-stage study tested the safety and how the body handles a single dose of ARC-520 given at different speeds. Forty healthy adults aged 18 to 55 took part. The main goal was to check for side effects, not to treat any disease.

This early-phase study tested the safety and how the body processes ARC-520 in 54 healthy adults aged 18-55. Participants received either the drug or a placebo, and researchers monitored side effects and drug levels in the blood. The goal was not to treat any disease but to gathe…